StockData
Vaccinex, Inc. logo

Vaccinex, Inc. (VCNX) stock

VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)

Close on Oct 19, 2026Market cap $3.22MP/E –Yield –

Vaccinex gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Vaccinex's gross profit for the twelve months ending Dec 31, 2020 was $623.00K, up 92.3% year over year. For fiscal 2020 it was $623.00K, up 92.3% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2020Dec 31, 2020$623.00K+92.3%
FY2019Dec 31, 2019$324.00K–
FY2018Dec 31, 2018-$309.00K–
FY2017Dec 31, 2017-$70.00K–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2020Dec 31, 2020$0-100.0%
Q3 FY2020Sep 30, 2020$623.00K–
Q4 FY2019Dec 31, 2019$0–
Q3 FY2019Sep 30, 2019$396.00K–
Q2 FY2019Jun 30, 2019$9.00K–
Q1 FY2019Mar 31, 2019-$81.00K–
Q4 FY2018Dec 31, 2018-$107.00K–
Q3 FY2018Sep 30, 2018-$48.00K–
Q2 FY2018Jun 30, 2018-$120.00K–
Q1 FY2018Mar 31, 2018-$34.00K–

More Vaccinex figures

See a number that looks wrong?